A Rapid and Automated Sample‐to‐Result HIV Load Test for Near‐Patient Application

Tanriverdi, Sultan; Chen, Lingjun; Chen, Shuqi

doi:10.1086/650387

Cited by 85 publications

(63 citation statements)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 This test, known as the Liat HIV Quant Assay (IQuum Inc., Marlborough, USA), uses whole blood in a single container for PCR amplification and analysis in 88 minutes. 44 The SAMBA HIV-1 test is a dipstick-based nucleic-acid assay for HIV detection and amplification. After collection of viral RNA, isothermal amplification of RNA is automated by a machine.…”

Section: Portable Testsmentioning

confidence: 99%

Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings

Zaman

2012

Bull. World Health Organ.

151

103

View full text Add to dashboard Cite

Section: Portable Testsmentioning

confidence: 99%

Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings

Zaman

2012

Bull. World Health Organ.

151

103

View full text Add to dashboard Cite

“…Both laboratory-developed and commercial molecular assays are now available, but the overall complexity of most of these tests has made implementation challenging for many clinical laboratories (18). However, significant recent advances in microfluidics, microelectronics, and microfabrication have allowed the development of simplified molecular systems that can be used by all laboratories regardless of their size, resources, or capacity (14,29,30,32,36). With this study, we compared one such commercial system, the eSensor XT-8 respiratory viral panel (eSensor RVP; GenMark Diagnostics, Inc., Carlsbad, CA), to laboratorydeveloped real-time PCR assays for the rapid detection of a number of respiratory viruses.…”

mentioning

confidence: 99%

Comparison of the GenMark Diagnostics eSensor Respiratory Viral Panel to Real-Time PCR for Detection of Respiratory Viruses in Children

Pierce

Hodinka

2012

J Clin Microbiol

View full text Add to dashboard Cite

A novel eSensor respiratory viral panel (eSensor RVP) multiplexed nucleic acid amplification test (GenMark Diagnostics, Inc., Carlsbad, CA) was compared to laboratory-developed real-time PCR assays for the detection of various respiratory viruses. A total of 250 frozen archived pediatric respiratory specimens previously characterized as either negative or positive for one or more viruses by real-time PCR were examined using the eSensor RVP. Overall agreement between the eSensor RVP and corresponding real-time PCR assays for shared analytes was 99.2% (kappa ‫؍‬ 0.96 [95% confidence interval {CI}, 0.94 to 0.98]). The combined positive percent agreement was 95.4% (95% CI, 92.5 to 97.3); the negative percent agreement was 99.7% (95% CI, 99.4 to 99.8). The mean real-time PCR threshold cycle (C T ) value for specimens with discordant results was 39.73 (95% CI, 38.03 to 41.43). Detection of coinfections and correct identification of influenza A virus subtypes were comparable between methods. Of note, the eSensor RVP rhinovirus assay was found to be more sensitive and specific than the corresponding rhinovirus real-time PCR. In contrast, the eSensor RVP adenovirus B, C, and E assays demonstrated some cross-reactivity when tested against known adenovirus serotypes representing groups A through F. The eSensor RVP is robust and relatively easy to perform, it involves a unique biosensor technology for target detection, and its multiplexed design allows for efficient and simultaneous interrogation of a single specimen for multiple viruses. Potential drawbacks include a slower turnaround time and the need to manipulate amplified product during the protocol, increasing the possibility of contamination.A cute viral upper and lower respiratory tract infections are responsible for substantial morbidity in both pediatric and adult populations worldwide. These infections can be severe and even fatal, especially in susceptible infants, older adults, patients with compromised immune systems, and individuals with underlying cardiopulmonary diseases. Rapid and accurate laboratory detection of respiratory viruses plays an important role in clinical management, guiding the appropriate prescription of antivirals, reducing the need for additional diagnostic studies and hospital procedures, and limiting the use of unnecessary antibiotics (2,4,5,6,10,19,31,35). In addition, a virologic diagnosis is instrumental to efforts focused on prevention of health care-associated infections (3,9,23,24).PCR has demonstrated superior sensitivity for the detection of respiratory viruses over the more conventional laboratory methods of virus culture and rapid direct antigen detection tests (7,12,20,22,34). Both laboratory-developed and commercial molecular assays are now available, but the overall complexity of most of these tests has made implementation challenging for many clinical laboratories (18). However, significant recent advances in microfluidics, microelectronics, and microfabrication have allowed the development of simplified molecular systems t...

show abstract

“…Tanriverdi et al adapted a commercially available HIV assay to fit a portable, fully integrated, and automated diagnostic system called Liat Analyzer [55]. 200-μL plasma is loaded into an assay tube and loaded into the analyzer that prepares the sample by performing viral lysis and nucleic acid conjugation with magnetic glass beads.…”

Section: ) Detection Of P24 Capsid Proteinsmentioning

confidence: 99%

“…The full process is depicted in Fig. 6 [55]. The fully integrated test is completed in 88 min and exhibits a limit of detection of 1000 copies/mL, leaving room for improvement to compete with the most rapid and sensitive technologies.…”

Section: ) Detection Of P24 Capsid Proteinsmentioning

confidence: 99%

Micro- and Nanotechnology for HIV/AIDS Diagnostics in Resource-Limited Settings

Damhorst

Watkins

Bashir

2013

IEEE Trans. Biomed. Eng.

View full text Add to dashboard Cite

A Rapid and Automated Sample‐to‐Result HIV Load Test for Near‐Patient Application

Abstract: Results suggest that the Liat HIV Quant Assay has performance equivalent to that of commercial HIV load assays and significantly reduces assay time, simplifies test operation, and provides biocontainment to allow operation in nonlaboratory settings.

Cited by 85 publications

References 5 publications

Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings

Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings

Comparison of the GenMark Diagnostics eSensor Respiratory Viral Panel to Real-Time PCR for Detection of Respiratory Viruses in Children

Micro- and Nanotechnology for HIV/AIDS Diagnostics in Resource-Limited Settings

Contact Info

Product

Resources

About